Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roniciclib plus platinum-etoposide versus placebo plus platinum-etoposide in first-line extensive-stage small cell lung cancer
2013-004198-28Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Roniciclib + platinum + etoposide with Placebo + platinum + etoposide (2 arms). Primary endpoint: Progression-free survival. Started Apr 2014; status: completed.
02
Drugs
roniciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2013-004198-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004198-28.